Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11681681 | 0.85 | KDM4E (0.42) | KDM4ECYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10740240 | 0.78 | CYP1A2 (0.49) | KDM4ECYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL11242237 | 0.76 | HPGD (0.43) | KDM4ECYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL16887859 | 0.75 | ALDH1A1 (0.36) | KMT2AALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL11767621 | 0.71 | KDM4E (0.70) | KDM4ECYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10052277 | 0.70 | MEN1 (0.34) | KMT2AALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL28039152 | 0.69 | KDM4E (0.44) | KDM4ECYP1A2SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL7746557 | 0.69 | ACHE (0.50) | KMT2ANPC1RAB9ALMNAMAPK1 | |
| SCHEMBL3443278 | 0.69 | KMT2A (0.44) | KDM4ECYP1A2CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL21814436 | 0.67 | ACHE (0.38) | KDM4EKMT2AALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1091760-A | Polyurethane mixture | ROHM & HAAS (US) | 1994-09-07 | — | — | CN | claimed |
| US-4146622-A | AZIRIDINYL QUINONE ANTI-TRANSPLANTED TUMOR AGENTS | THE GOVERNMENT OF THE UNITED STATES (US) | 1979-03-27 | — | — | US | claimed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-107078217-A | Semiconductor composition comprising inorganic semiconductor material and organic bond | 默克专利股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-8802161-B2 | Herbal composition and method of use for the treatment of cancer | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20100209388-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | FLORIDA A & M UNIVERSITY | 2010-08-19 | — | — | US | disclosed |
| US-20070248693-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | MAZZIO ELIZABETH | 2007-10-25 | — | — | US | disclosed |
| US-20060035981-A1 | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment | MAZZIO ELIZABETH A | 2006-02-16 | — | — | US | disclosed |
| WO-2006017494-A2 | INHIBITION OF ANAEROBIC GLUCOSE METABOLISM | MAZZIO ELIZABETH (US) | 2006-02-16 | — | — | WO | disclosed |
| CN-1050622-C | Polyurethane mixture | ROHM & HAAS (US) | 2000-03-22 | — | — | CN | disclosed |
| US-4704384-A | BRAIN TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0060258-A4 | METHOD FOR PRODUCING 3,6-BIS(CARBOETHOXYAMINO)-2,5-DIAZIRIDINYL-1,4-BENZOQUINONE. | AEROJET GENERAL CO (US) | 1982-12-02 | — | — | EP | disclosed |
| EP-0060258-A1 | METHOD FOR PRODUCING 3,6-BIS(CARBOETHOXYAMINO)-2,5-DIAZIRIDINYL-1,4-BENZOQUINONE. | AEROJET GENERAL CO (US) | 1982-09-22 | — | — | EP | disclosed |
| WO-1982000823-A1 | METHOD FOR PRODUCING 3,6-BIS(CARBOETHOXYAMINO)-2,5-DIAZIRIDINYL-1,4-BENZOQUINONE | AEROJET GENERAL CO (US) | 1982-03-18 | — | — | WO | disclosed |
| US-4233215-A | Aziridinyl quinone antitumor agents | UNITED STATES OF AMERICA (US) | 1980-11-11 | — | — | US | disclosed |
| US-4233215-A | Aziridinyl quinone antitumor agents | UNITED STATES OF AMERICA (US) | 1980-11-11 | — | — | US | disclosed |
| US-4146622-A | AZIRIDINYL QUINONE ANTI-TRANSPLANTED TUMOR AGENTS | THE GOVERNMENT OF THE UNITED STATES (US) | 1979-03-27 | — | — | US | disclosed |
| US-4146622-A | AZIRIDINYL QUINONE ANTI-TRANSPLANTED TUMOR AGENTS | THE GOVERNMENT OF THE UNITED STATES (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209388-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | DLD, MDH1, MDH2 | KDM4E 957/4885CYP1A2 1919/4885CYP2C9 3155/4885 |
| US-20060035981-A1 | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment | G6PD, PDK2, SDHA | KDM4E 1094/4885CYP1A2 352/4885CYP2C9 668/4885 |
| US-20070248693-A1 | Nutraceutical composition and method of use for treatment / prevention of cancer | DLD, DERA, ALDOA | KDM4E 522/4885CYP1A2 1609/4885CYP2C9 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.